<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02498509</url>
  </required_header>
  <id_info>
    <org_study_id>153PAR14017</org_study_id>
    <nct_id>NCT02498509</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy and Safety of CKD-342</brief_title>
  <official_title>A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Concomitant Mometasone Furoate and Levocabastine HCl in Perennial Allergic Rhinitis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical Trial to Evaluate the Efficacy and Safety of CKD-342&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Double-blind, Active-controlled, Multicenter phase 3 Clinical trial to evaluate&#xD;
      the Efficacy and Safety of Concomitant Mometasone furoate and Levocabastine HCl in Perennial&#xD;
      Allergic Rhinitis patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in rTNSS from baseline</measure>
    <time_frame>up to week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in rTNSS from baseline</measure>
    <time_frame>up to week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in AM rTNSS and PM rTNSS from baseline</measure>
    <time_frame>2 weeks and 4 weeks after the baseline assessment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician assessed overall nasal symptom from baseline</measure>
    <time_frame>2 weeks and 4 weeks after the basline assessment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in RQLQ</measure>
    <time_frame>2 weeks and 4 weeks after the baseline assessment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changing in 4 nasal symptom score (sneezing, runny nose, nasal congestion, itchy nose) from baseline</measure>
    <time_frame>2 weeks and 4 weeks after the basline assessment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">459</enrollment>
  <condition>Rhinitis, Allergic, Perennial</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-342</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mometasone furoate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levocabastine HCL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-342</intervention_name>
    <description>treatment for 4 weeks after randomization</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>investigational product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone furoate</intervention_name>
    <description>treatment for 4 weeks after randomization</description>
    <arm_group_label>Control 1</arm_group_label>
    <other_name>investigational product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levocabastine HCL</intervention_name>
    <description>treatment for 4 weeks after randomization</description>
    <arm_group_label>Control 2</arm_group_label>
    <other_name>investigational product</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. male, female, Age: over 13 years(no age limiation in upper)&#xD;
&#xD;
          2. subject who has experienced perennial allergic rhinitis for over 1 year&#xD;
&#xD;
          3. subject who has identified allergens throughout the year within 12 months&#xD;
&#xD;
          4. subject who has the symptoms of moderate to severe allergic rhinitis&#xD;
&#xD;
          5. subject who can record the the patient diary during the clinical trial period&#xD;
&#xD;
          6. subject who agreed to keep the same environment during the clinical trial period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Asthma&#xD;
&#xD;
          2. Previous medical history at screening (Nasal polyps within the previous two months,&#xD;
             biopsies, ulcers, trauma, surgery, atrophic rhinitis, patients with a history of drug&#xD;
             rhinitis)&#xD;
&#xD;
          3. Patients with untreated localized infection in nasal mucosa&#xD;
&#xD;
          4. Patients following administration of a combination of prohibited drugs in patients&#xD;
             administered concomitant medications or trial period is expected to be inevitable&#xD;
&#xD;
          5. Patients with abnormal following laboratory test results at screening&#xD;
&#xD;
               -  AST, ALT&gt;2times the upper limit of normal at screening&#xD;
&#xD;
               -  Serum creatinine &gt;1.5times the upper limit of normal at screening&#xD;
&#xD;
          6. Previous history of acute or severe chronic sinusitis within 30 days at screening&#xD;
&#xD;
          7. The continue use of drugs that may affect the efficacy of the Investigational product&#xD;
&#xD;
          8. Start the immunotherapy or a change of doge within 1 month, at screening&#xD;
&#xD;
          9. If you have glaucoma or cataracts, herpes simplex, or around the eyes&#xD;
&#xD;
         10. Chronic obstructive pulmonary disease (COPD)&#xD;
&#xD;
         11. history of hypersensitivity reactions and for treaties or major components of the IP&#xD;
&#xD;
         12. Pregnant women, breast feeding women or women of childbearing potential must agree to&#xD;
             use appropriate contraception methods&#xD;
&#xD;
         13. Alcohol or illegal drug abuse or dependence in patients&#xD;
&#xD;
         14. participation in any investigational or maketed drug within 4weeks preceding the&#xD;
             screening visit&#xD;
&#xD;
         15. Patients that can not be participating in a clinical trial by investigator's&#xD;
             discretion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Irwon-dong</city>
        <state>Gangnam-gu, Seoul</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>July 5, 2015</study_first_submitted>
  <study_first_submitted_qc>July 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2015</study_first_posted>
  <last_update_submitted>December 22, 2016</last_update_submitted>
  <last_update_submitted_qc>December 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Levocabastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

